These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31683810)

  • 1. Antibody-Based Targeting of Cell Surface GRP94 Specifically Inhibits Cetuximab-Resistant Colorectal Cancer Growth.
    Jeoung MH; Kim TK; Kim JW; Cho YB; Na HJ; Yoo BC; Shim H; Song DK; Heo K; Lee S
    Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31683810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An internalizing antibody targeting of cell surface GRP94 effectively suppresses tumor angiogenesis of colorectal cancer.
    Cho YB; Kim JW; Heo K; Kim HJ; Yun S; Lee HS; Shin HG; Shim H; Yu H; Kim YH; Lee S
    Biomed Pharmacother; 2022 Jun; 150():113051. PubMed ID: 35658213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
    Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
    Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
    Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
    Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab.
    Ma H; Wu Z; Peng J; Li Y; Huang H; Liao Y; Zhou M; Sun L; Huang N; Shi M; Bin J; Liao Y; Rao J; Wang L; Liao W
    Int J Cancer; 2018 Jun; 142(12):2578-2588. PubMed ID: 29363109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
    Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
    Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock protein 70-2 (HSP70-2) is a novel therapeutic target for colorectal cancer and is associated with tumor growth.
    Jagadish N; Parashar D; Gupta N; Agarwal S; Suri V; Kumar R; Suri V; Sadasukhi TC; Gupta A; Ansari AS; Lohiya NK; Suri A
    BMC Cancer; 2016 Jul; 16():561. PubMed ID: 27473057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
    Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
    Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer.
    Li C; Singh B; Graves-Deal R; Ma H; Starchenko A; Fry WH; Lu Y; Wang Y; Bogatcheva G; Khan MP; Milne GL; Zhao S; Ayers GD; Li N; Hu H; Washington MK; Yeatman TJ; McDonald OG; Liu Q; Coffey RJ
    Proc Natl Acad Sci U S A; 2017 Apr; 114(14):E2852-E2861. PubMed ID: 28320945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer.
    Park SH; Jo MJ; Kim BR; Jeong YA; Na YJ; Kim JL; Jeong S; Yun HK; Kim DY; Kim BG; Kang SH; Oh SC; Lee DH
    Theranostics; 2019; 9(8):2235-2251. PubMed ID: 31149041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer.
    Hou Z; Sun L; Xu F; Hu F; Lan J; Song D; Feng Y; Wang J; Luo X; Hu J; Wang G
    Cancer Lett; 2020 Sep; 487():63-73. PubMed ID: 32473242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
    Nakadate Y; Kodera Y; Kitamura Y; Shirasawa S; Tachibana T; Tamura T; Koizumi F
    Int J Cancer; 2014 May; 134(9):2146-55. PubMed ID: 24136682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines.
    Kim S; Kim N; Kang K; Kim W; Won J; Cho J
    Cells; 2019 Aug; 8(8):. PubMed ID: 31409052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.
    Jia YT; Yang DH; Zhao Z; Bi XH; Han WH; Feng B; Zhi J; Gu B; Duan Z; Wu JH; Ju YC; Wang MX; Li ZX
    Curr Cancer Drug Targets; 2018; 18(3):278-286. PubMed ID: 28359236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
    Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
    Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
    Yoon J; Koo KH; Choi KY
    Cancer Res; 2011 Jan; 71(2):445-53. PubMed ID: 21118963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Cetuximab-Conjugated Gold Nanoparticles on the Cytotoxicity and Phenotypic Evolution of Colorectal Cancer Cells.
    El Hallal R; Lyu N; Wang Y
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cell surface glucose-regulated protein 94 in gastric cancer with an anti-GRP94 human monoclonal antibody.
    Kim HJ; Cho YB; Heo K; Kim JW; Shin HG; Lee EB; Park SM; Park JB; Lee S
    BMB Rep; 2024 Apr; 57(4):188-193. PubMed ID: 38449302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.